Eli Lilly has entered into a $2.75 billion partnership with Hong Kong‑listed Insilico Medicine, giving Lilly exclusive worldwide rights to develop, manufacture and commercialize drugs discovered through Insilico’s generative AI platform across multiple therapeutic areas. The agreement includes an upfront payment of $115 million, with the remaining $2.635 billion contingent on regulatory and commercial milestones and royalty payments on future sales.
Under the terms of the deal, Insilico will join Lilly’s Gateway Labs community, providing access to its AI tools and early‑stage research capabilities. The milestone‑based payment structure aligns the interests of both companies, ensuring that Lilly pays additional sums only when pre‑clinical candidates progress through development and achieve regulatory approval or commercial success.
The partnership expands Lilly’s AI strategy, which already includes a $1 billion commitment to Nvidia‑powered AI infrastructure and a series of prior AI‑focused deals, such as a November 2025 research agreement worth over $100 million and an initial licensing agreement in 2023. Insilico’s platform, known as Pharma.AI, leverages deep‑learning models to identify multi‑purpose targets and accelerate the nomination of pre‑clinical candidates, typically within 12–18 months per program. The collaboration is expected to shorten drug‑development timelines and reduce R&D costs by harnessing Insilico’s dual‑engine model that combines AI with in‑house discovery capabilities.
Management commentary underscores the strategic fit: "We are delighted to collaborate with Lilly, a global leader in the pharmaceutical industry, renowned for its commitment to medical innovation," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. "Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognizes Insilico’s AI‑driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide." Andrew Adams, Group Vice President of Molecule Discovery at Lilly, added, "Insilico’s AI‑enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas. This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas."
Eli Lilly’s recent financial performance provides a strong backdrop for the deal. The company’s obesity and type 2 diabetes drugs, Zepbound and Mounjaro, have propelled it into the $1 trillion market‑cap club, and its $1 billion Nvidia investment demonstrates its commitment to AI infrastructure. Insilico, meanwhile, secured a $110 million Series E round in January 2025 to advance its platform and drug pipeline, and has entered partnerships with Menarini Group, Servier, and Qilu Pharmaceutical. Lilly’s acquisitions of Ventyx Biosciences and Orna Therapeutics in early 2026 further illustrate its strategy to broaden its pipeline and leverage complementary technologies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.